A Safety Study of SEA-BCMA in Patients With Multiple Myeloma
NCT03582033
Terminated
This trial will study SEA-BCMA to find out whether it is an effective treatment for multiple myeloma (MM) and what side effects (unwanted effects) may occur. The study will have several parts. In Parts A and B, participants get SEA-BCMA by itself. This part of the study will find out how much SEA-BCMA should be given for treatment and how often. It will also find out how safe the treatment is and how well it works. In Part C of the study, participants will get SEA-BCMA and dexamethasone. In Pa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2024
Locations: Stanford University School of Medicine, Palo Alto, California +12 locations
Conditions: Multiple Myeloma
Register for Updates
Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
NCT04191616
Completed
A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
11/01/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +45 locations
Conditions: Relapsed or Refractory Multiple Myeloma
Register for Updates
Pivotal Study of OCS-01 Eye Drops in Subjects with Diabetic Macular Edema (DIAMOND-2)
NCT06172257
Recruiting
The primary objective is to evaluate the efficacy and safety of OCS 01 as compared to Vehicle in subjects with Diabetic Macular Edema (DME).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/31/2024
Locations: Oculis Investigative Site - Stanford Byers Eye Institute, Palo Alto, California
Conditions: Diabetic Macular Edema
Register for Updates
Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma
NCT03399539
Completed
This phase I trial studies the side effects and best dose of venetoclax when given together with ixazomib citrate and dexamethasone and to see how well they work in treating patients with multiple myeloma that has come back. Venetoclax and ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2024
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan +2 locations
Conditions: Recurrent Plasma Cell Myeloma, t(11;14)
Register for Updates
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
NCT04892446
Completed
The goal of this clinical study is to learn more about the safety and dosing of the study drug, magrolimab, in combination with other anticancer therapies in participants with relapsed/refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2024
Locations: Arizona Oncology Associates , PC - HOPE, Tucson, Arizona +21 locations
Conditions: Multiple Myeloma
Register for Updates
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
NCT04270409
Active Not Recruiting
Primary Objectives: * Safety run-in Part: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM) * Randomized Phase 3 Part: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival when compared to lenalidomide and dexamethasone in subjects with high-risk SMM Secondary Objectives: Safety run-in Pa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2024
Locations: UCLA Site Number : 8400010, Los Angeles, California +104 locations
Conditions: Plasma Cell Myeloma
Register for Updates
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
NCT03589326
Active Not Recruiting
In this study, adults with newly-diagnosed Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) will receive first-line therapy of ponatinib or imatinib. The main aim of this study is to compare the number of participants on each treatment that show no signs of disease. Participants will take tablets of either ponatinib or imatinib at the same time each day combined with reduced-intensity chemotherapy for up to 20 months. Then, they will continue with single-agent therapy (p... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +91 locations
Conditions: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
Register for Updates
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
NCT04546399
Suspended
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occu... Read More
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
10/29/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama +202 locations
Conditions: Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Register for Updates
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
NCT02339740
Active Not Recruiting
This phase III trial studies tretinoin and arsenic trioxide in treating patients with newly diagnosed acute promyelocytic leukemia. Standard treatment for acute promyelocytic leukemia involves high doses of a common class of chemotherapy drugs called anthracyclines, which are known to cause long-term side effects, especially to the heart. Tretinoin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Arsenic trioxide may stop the growth of cancer cells by e... Read More
Gender:
ALL
Ages:
Between 12 months and 21 years
Trial Updated:
10/28/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama +173 locations
Conditions: Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
Register for Updates
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
NCT05028348
Recruiting
This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an immunomodulatory imide drug (IMiD), proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody (mAb).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: The University of Arizona Cancer Center, Tucson, Arizona +93 locations
Conditions: Multiple Myeloma
Register for Updates
Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
NCT05289492
Terminated
This is a multicenter, open-label, phase I/II clinical study, to assess the safety, tolerability, antitumor activity, pharmacokinetics and pharmacodynamics of EOS884448 (also known as EOS-448 or GSK4428859A), alone or in combination with iberdomide with and without dexamethasone in participants with relapsed/refractory multiple myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2024
Locations: Banner MD Anderson, Gilbert, Arizona +12 locations
Conditions: Multiple Myeloma
Register for Updates
Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies
NCT04776850
Withdrawn
This clinical trial studies the effect of pre-transplant immunosuppression (PTIS) and donor stem cell transplant in treating patients with severe blood diseases (hemoglobinopathies). PTIS helps prepare the body for the transplant and lowers the risk of developing graft versus host disease (GVHD). Hematopoietic cells are found in the bone marrow and produce blood cells. Hematopoietic cell transplantation (HCT) injects healthy hematopoietic cells into the body to support blood cell production. PTI... Read More
Gender:
ALL
Ages:
Between 2 years and 30 years
Trial Updated:
10/22/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Beta Thalassemia Major, Sickle Beta 0 Thalassemia, Sickle Beta Plus Thalassemia, Sickle Beta Thalassemia, Sickle Cell Disease, Sickle Cell-SS Disease
Register for Updates